Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04741646 · ClinicalTrials.gov registry record · Phase 2

Ferric Citrate and Chronic Kidney Disease in Children

A Phase 2 study of Chronic Kidney Diseases, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Phase 2
Development phase
160
Enrollment target
20
Study locations

NCT04741646 is a Phase 2 study of Chronic Kidney Diseases that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 160 participants, below the 443-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04741646, a Phase 2 study of Chronic Kidney Diseases, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Phase 2
Development phase
160 participants
Enrollment target
20
Study locations

Study Summary

We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 20 core clinical sites.

Conditions Studied

Chronic Kidney Diseases

Interventions

  • DRUG Placebo
  • DRUG Ferric Citrate

Study Locations (20)

California

  • University of California, Los Angeles - Los Angeles
  • Children's Hospital of Orange County - Orange
  • University of California, San Francisco - San Francisco

Texas

  • Children's Medical Center, Dallas - Dallas
  • Baylor College of Medicine - Houston
  • UTH - Houston

Missouri

  • Children's Mercy Hospital, Kansas City - Kansas City
  • Washington U - St Louis

New York

  • Cohen's Childrens - New York
  • Children's Hospital at Montefiore - The Bronx

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati
  • Nationwide Children's - Columbus

Florida

  • Arnold Palmer Hospital for Children - Orlando

Georgia

  • Emory University - Atlanta

Indiana

  • Indiana U - Indianapolis

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2022-06-17
Est. Completion 2027-10
Phase Phase 2

Sponsor

University of California, Los Angeles

897 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04741646

The ClinicalTrials.gov registry entry for NCT04741646 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 443-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (64% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04741646 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Texas, Missouri.

Frequently Asked Questions

What is clinical trial NCT04741646 about?

NCT04741646 is a clinical study titled "Ferric Citrate and Chronic Kidney Disease in Children". We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidn...

What is the current status of trial NCT04741646?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2022-06-17. Estimated completion is 2027-10.

What conditions does trial NCT04741646 study?

This clinical trial studies the following conditions: Chronic Kidney Diseases.

What interventions are being tested in trial NCT04741646?

The interventions under investigation include: Placebo (DRUG), Ferric Citrate (DRUG).

Who is sponsoring clinical trial NCT04741646?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04741646 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Kidney Diseases

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.